Nilotinib-loaded hydroxy propyl β-cyclodextrin nanosponges for improved oral bioavailability in chronic myeloid leukemia therapy
DARU Journal of Pharmaceutical Sciences · 12.08.2026 · 34 (2)
DOI: 10.1007/s40199-026-00641-x ↗Kurz gefasst
Fachartikel in der Zeitschrift DARU Journal of Pharmaceutical Sciences, online erschienen am 12.08.2026. Verfasst von Bhagya Buela Gudipalli und 10 weiteren Autor:innen. Beteiligte Einrichtung: KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vijayawada, India. Hauptthemen laut MEDLINE: 2-Hydroxypropyl-beta-cyclodextrin, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Pyrimidines, Drug Carriers. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVE: Poor aqueous solubility and low permeability limit the oral bioavailability of Nilotinib, a second-generation tyrosine kinase inhibitor used in chronic myeloid leukemia. Nanosponges prepared using cyclodextrin derivatives offer a scalable and efficient platform for enhancing solubility, controlling release, and improving bioavailability. Therefore, this study aimed to formulate Nilotinib-loaded hydroxypropyl β-cyclodextrin nanosponges to enhance oral absorption. METHODS: Hydroxypropyl β-cyclodextrin nanosponges were synthesized using diphenyl carbonate as a cross-linker. Box-Behnken Design, under a Quality-by-Design framework, was applied to optimize critical parameters including mixing speed, reaction time, and molar ratio. The optimized formulation was characterized for particle size, zeta potential, entrapment efficiency, morphology, compatibility, drug release, permeability, and pharmacokinetic performance in rats. RESULTS: The optimized nanosponges showed a particle size of 203.1 ± 3.1 nm, zeta potential of - 24.0 ± 2.55 mV, and entrapment efficiency of 66.88 ± 2.66%. SEM confirmed a uniform porous structure. In vitro release and permeability demonstrated enhanced performance compared to pure drug. Pharmacokinetic evaluation revealed a 2.68-fold increase in AUC₀₋ₜ, indicating improved oral bioavailability. CONCLUSION: Nilotinib-loaded hydroxypropyl β-cyclodextrin nanosponges significantly enhanced dissolution, permeability, and systemic exposure, suggesting a promising and scalable strategy to improve the therapeutic performance of Nilotinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vijayawada, India.
- Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Saugor, India.
- Department of Pharmacognosy, Vel Pharmacy College, Vels University VISTAS, Chennai, India.
- Department of Pharmaceutics,School of pharmacy, aditya university, surampalem, India.
- Department of Pharmaceutical Engineering, Indian Institute of Technology BHU, Varanasi, India.
- KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vijayawada, India. visu486@gmail.com.
Zitieren
APA
Gudipalli, B. B., Av, S., Kakarla, R., Pawde, D. M., G, A. K., Thummala, U., Singh, S., Guntupalli, C., Nalluri, B. N., Madaswamy, S. M., & Matte, K. V. (2026). Nilotinib-loaded hydroxy propyl β-cyclodextrin nanosponges for improved oral bioavailability in chronic myeloid leukemia therapy. DARU Journal of Pharmaceutical Sciences, 34(2). https://doi.org/10.1007/s40199-026-00641-x
Vancouver
Gudipalli BB, Av S, Kakarla R, Pawde DM, G AK, Thummala U, et al. Nilotinib-loaded hydroxy propyl β-cyclodextrin nanosponges for improved oral bioavailability in chronic myeloid leukemia therapy. DARU Journal of Pharmaceutical Sciences. 2026;34(2). doi:10.1007/s40199-026-00641-x
BibTeX
@article{Gudipalli2026,
author = {Gudipalli, Bhagya Buela and Av, Surendra and Kakarla, Ramakrishna and Pawde, Datta Maroti and G, Avinash Kumar and Thummala, Udaykumar and Singh, Shailendra and Guntupalli, Chakravarthi and Nalluri, Buchi N and Madaswamy, Sona Muthu and Matte, Kasi Viswanadh},
title = {Nilotinib-loaded hydroxy propyl β-cyclodextrin nanosponges for improved oral bioavailability in chronic myeloid leukemia therapy},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2026},
volume = {34},
number = {2},
doi = {10.1007/s40199-026-00641-x}
}
EUVIMED